These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Cell surface antigens of melanocytes and melanoma. Albino AP; Houghton AN Cancer Surv; 1985; 4(1):185-211. PubMed ID: 3842314 [TBL] [Abstract][Full Text] [Related]
43. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells. Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057 [TBL] [Abstract][Full Text] [Related]
44. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Sun Y; Jurgovsky K; Möller P; Alijagic S; Dorbic T; Georgieva J; Wittig B; Schadendorf D Gene Ther; 1998 Apr; 5(4):481-90. PubMed ID: 9614572 [TBL] [Abstract][Full Text] [Related]
45. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529 [TBL] [Abstract][Full Text] [Related]
46. Use of formalin-fixed melanoma cells for the detection of antibodies against surface antigens by a micro-immune adherence technique. Müller C; Sorg C Eur J Immunol; 1975 Mar; 5(3):175-8. PubMed ID: 1234054 [TBL] [Abstract][Full Text] [Related]
47. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882 [TBL] [Abstract][Full Text] [Related]
48. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. Shiku H; Takahashi T; Oettgen HF J Exp Med; 1976 Oct; 144(4):873-81. PubMed ID: 978138 [TBL] [Abstract][Full Text] [Related]
49. Serological analysis of cell surface antigens of malignant human brain tumors. Pfreundschuh M; Shiku H; Takahashi T; Ueda R; Ransohoff J; Oettgen HF; Old LJ Proc Natl Acad Sci U S A; 1978 Oct; 75(10):5122-6. PubMed ID: 283420 [TBL] [Abstract][Full Text] [Related]
50. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Livingston PO; Takeyama H; Pollack MS; Houghton AN; Albino A; Pinsky CM; Oettgen HF; Old LJ Int J Cancer; 1983 May; 31(5):567-75. PubMed ID: 6852975 [TBL] [Abstract][Full Text] [Related]
51. Antibody-induced movement of common melanoma membrane antigens on the surface of unfixed human melanoma cells. Leong SP; Cooperband SR; Deckers PJ; Sutherland CM; Cesare JF; Krementz ET Cancer Res; 1979 Jun; 39(6 Pt 1):2125-31. PubMed ID: 376115 [TBL] [Abstract][Full Text] [Related]
52. Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. Chee DO; Boddie AW; Roth JA; Holmes EC; Morton DL Cancer Res; 1976 Apr; 36(4):1503-9. PubMed ID: 1260767 [TBL] [Abstract][Full Text] [Related]